References
- Aitken, Murray, Ernst R. Berndt, David Cutler, Michael Kleinrock, and Luca Maini. 2016. “Has the Era of Slow Growth for Prescription Drug Spending Ended?” Health Affairs (Project Hope) 35 (9): 1595–1603.
- Aitken, Murray L., and Michael Kleinrock. 2018. “Medicines Use and Spending in the U.S.: A Review of 2017 and Outlook to 2022.” Parsippany, NJ: IQVIA Institute for Human Data Science. https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/medicine-use-and-spending-in-the-us-a-review-of-2017-and-outlook-to-2022.pdf.
- Alpern, Jonathan D., William M. Stauffer, and Aaron S. Kesselheim. 2014. “High-Cost Generic drugs - implications for patients and policymakers.” The New England Journal of Medicine 371 (20): 1859–1862.
- Berndt, Ernst R., and Murray L. Aitken. 2011. “Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation.” International Journal of the Economics of Business 18 (2): 177–201.
- Berndt, Ernst R., Rena M. Conti, and Stephen J. Murphy. 2017. “The Landscape of US Generic Prescription Drug Markets, 2004-2016.” National Bureau of Economic Research, Working Paper no. 23640.
- Berndt, Ernst R., Rena M. Conti, and Stephen J. Murphy. 2018. “The Generic Drug User Fee Amendments: An Economic Perspective.” Journal of Law and the Biosciences 5 (1): 103–141.
- Berndt, Ernst R., and Pierre Dubois. 2016. “Impacts of Patent Expiry on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010.”International Journal of the Economics of Business 23 (2): 125–147.
- Berndt, Ernst R., Richard Mortimer, Ashoke Bhattacharjya, Andrew Parece, and Edward Tuttle. 2007. “Authorized Generic Drugs, Price Competition, and consumers’ welfare.” Health Affairs (Project Hope) 26 (3): 790–799.
- Berndt, Ernst R., and Joseph P. Newhouse. 2012. “Pricing and Reimbursement in U.S. Pharmaceutical Markets.” In The oxford handbook of the economics of the biopharmaceutical industry, edited by P. M. Danzon and S. Nicholson, 201–265. New York, NY: Oxford University Press.
- Collins, Susan M., and Claire McCaskill. 2016. Sudden Price Spikes in Off-Patent Prescription Drugs, the Monopoly Business Model that Harms Patients, Taxpayers, and The US Health Care System, 114–429. Washington, DC: US Government Publishing Office. https://www.congress.gov/114/crpt/srpt429/CRPT-114srpt429.pdf.
- Conti, Rena M., and Ernst R. Berndt. 2014. “Specialty Drug Prices and Utilization After Loss of U.S. Patent Exclusivity, 2001–2007.” http://proxy.uchicago.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=eoh&AN=1440021&site=ehost-live&scope=site.
- Dave, Chintan V., Aaron S. Kesselheim, Erin R. Fox, Peihua Qiu, and Abraham Hartzema. 2017. “High Generic Drug Prices and Market Competition: A Retrospective Cohort Study.” Annals of Internal Medicine 167 (3): 145–151.
- Drake, Keith M., and Thomas G. McGuire. 2016. “Stock Price Evidence for Anticompetitive Effects in the Nexium ‘Reverse-Payment’ Settlement.” Journal of Competition Law & Economics 12 (4): 735–747.
- Drake, Keith M., Martha A. Starr, and Thomas G. McGuire. 2015. “Do ‘Reverse Payment’ Settlements Constitute an Anticompetitive Pay-for-Delay?” International Journal of the Economics of Business 22 (2): 173–200.
- Dusetzina, Stacie B., Rena M. Conti, L. Nancy Yu, and Peter B. Bach. 2017. “Association of Prescription Drug Price Rebates in Medicare Part D with Patient out-of-Pocket and Federal Spending.” JAMA Internal Medicine 177 (8): 1185–1188.
- “Federal Reserve Board Economic Data”. 2018. Federal Reserve Bank of St. Louis. 2018. https://fred.stlouisfed.org/series/A191RI1Q225SBEA.
- Lichtenberg, Frank R. 2009. “International Differences in Cancer Survival Rates: The Role of New Drug Launches.” International Journal of Healthcare Technology and Management 10 (3): 138–155.
- McGuire, Thomas, Keith Drake, Einer Ethauge, Raymond Hartman, and Martha Starr. 2016. “Resolving Reverse-Payment Settlements with the Smoking Gun of Stock Price Movements.” Iowa Law Review 101 (4): 1581–1599.
- Silverman, Ed. 2014. “Lawmakers Probe ‘Staggering’ Price Hikes for Generic Drugs.” Wall Street Journal, October 2, 2014. https://blogs.wsj.com/pharmalot/2014/10/02/lawmakers-probe-staggering-price-hikes-for-generic-drugs/.
- US Department of Health and Human Services. 2018. “American Patients First.” Washington, DC: US Department of Health and Human Services. https://www.hhs.gov/sites/default/files/AmericanPatientsFirst.pdf.
- US Food and Drug Administration. 2017. “FDA Tackles Drug Competition to Improve Patient Access: Agency Takes Important Steps under New Drug Competition Action Plan.” US Food and Drug Administration, June 27, 2017. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm564725.htm.
- Whinston, Michael D. 2007. “Antitrust Policy Toward Horizontal Mergers.” In Handbook of Industrial Organization, vol. 3, pp. 2369–2440. Amsterdam: North Holland Elsevier.